Literature DB >> 7964823

Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease or vascular dementia.

J Kawamata1, S Tanaka, S Shimohama, K Ueda, J Kimura.   

Abstract

Apolipoprotein E (ApoE) plays a key part in lipid metabolism both in the liver, and in the CNS. To clarify the association of ApoE polymorphism with Alzheimer's disease and vascular dementia in Japan, 13 patients with early onset (age > or = 65) sporadic Alzheimer's disease, 40 patients with late onset (age < or = 65) sporadic Alzheimer's disease, 19 patients with vascular dementia, and 49 non-demented control subjects were analysed. The results showed a significantly increased frequency of the epsilon 4 allele in the patients with late onset sporadic Alzheimer's disease (0.25), but not in the patients with early onset sporadic Alzheimer's disease (0.04) or in the patients with vascular dementia (0.13) compared with controls (0.09). The raised frequency of the epsilon 4 allele in the patients with late onset sporadic Alzheimer's disease was of a lower magnitude than that in United States and Canadian studies. This may in part be due to a lower epsilon 4 frequency in the normal Japanese population and reflect the lower morbidity from Alzheimer's disease in Japan.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7964823      PMCID: PMC1073199          DOI: 10.1136/jnnp.57.11.1414

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  11 in total

1.  Plasma apolipoproteins in patients with multi-infarct dementia.

Authors:  H Shimano; S Ishibashi; T Murase; T Gotohda; N Yamada; F Takaku; E Ohtomo
Journal:  Atherosclerosis       Date:  1989-10       Impact factor: 5.162

2.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease.

Authors:  Y Namba; M Tomonaga; H Kawasaki; E Otomo; K Ikeda
Journal:  Brain Res       Date:  1991-02-08       Impact factor: 3.252

3.  Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease. A case-control study.

Authors:  R Couderc; F Mahieux; S Bailleul; G Fenelon; R Mary; J Fermanian
Journal:  Stroke       Date:  1993-05       Impact factor: 7.914

4.  Apolipoprotein E polymorphism and Alzheimer's disease.

Authors:  J Poirier; J Davignon; D Bouthillier; S Kogan; P Bertrand; S Gauthier
Journal:  Lancet       Date:  1993-09-18       Impact factor: 79.321

5.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

6.  Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions.

Authors:  G W Rebeck; J S Reiter; D K Strickland; B T Hyman
Journal:  Neuron       Date:  1993-10       Impact factor: 17.173

7.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

Authors:  G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

8.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

Authors:  A M Saunders; W J Strittmatter; D Schmechel; P H George-Hyslop; M A Pericak-Vance; S H Joo; B L Rosi; J F Gusella; D R Crapper-MacLachlan; M J Alberts
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

Review 9.  Apolipoprotein E polymorphism in health and disease.

Authors:  G Utermann
Journal:  Am Heart J       Date:  1987-02       Impact factor: 4.749

Review 10.  Apolipoprotein E polymorphism and atherosclerosis.

Authors:  J Davignon; R E Gregg; C F Sing
Journal:  Arteriosclerosis       Date:  1988 Jan-Feb
View more
  8 in total

Review 1.  Is apolipoprotein E4 an important risk factor for vascular dementia?

Authors:  Troy T Rohn
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging.

Authors:  Ging-Yuek R Hsiung; A Dessa Sadovnick; Howard Feldman
Journal:  CMAJ       Date:  2004-10-12       Impact factor: 8.262

3.  Apolipoprotein E, angiotensin-converting enzyme and kallikrein gene polymorphisms and the risk of Alzheimer's disease and vascular dementia.

Authors:  H K Wang; H C Fung; W C Hsu; Y R Wu; J C Lin; L S Ro; K H Chang; F J Hwu; Y Hsu; S Y Huang; G J Lee-Chen; C M Chen
Journal:  J Neural Transm (Vienna)       Date:  2006-02-09       Impact factor: 3.575

Review 4.  Genetic testing in dementia - utility and clinical strategies.

Authors:  Carolin A M Koriath; Joanna Kenny; Natalie S Ryan; Jonathan D Rohrer; Jonathan M Schott; Henry Houlden; Nick C Fox; Sarah J Tabrizi; Simon Mead
Journal:  Nat Rev Neurol       Date:  2020-11-09       Impact factor: 42.937

5.  Apolipoprotein E4 frequencies in a Japanese population with Alzheimer's disease and dementia with Lewy bodies.

Authors:  Seiju Kobayashi; Masaru Tateno; Tae Woo Park; Kumiko Utsumi; Hitoshi Sohma; Yoichi M Ito; Yasuo Kokai; Toshikazu Saito
Journal:  PLoS One       Date:  2011-04-28       Impact factor: 3.240

Review 6.  Role of Apolipoproteins and α-Synuclein in Parkinson's Disease.

Authors:  Fatemeh Nouri Emamzadeh
Journal:  J Mol Neurosci       Date:  2017-07-10       Impact factor: 3.444

7.  Non-coding variability at the APOE locus contributes to the Alzheimer's risk.

Authors:  Xiaopu Zhou; Yu Chen; Kin Y Mok; Timothy C Y Kwok; Vincent C T Mok; Qihao Guo; Fanny C Ip; Yuewen Chen; Nandita Mullapudi; Paola Giusti-Rodríguez; Patrick F Sullivan; John Hardy; Amy K Y Fu; Yun Li; Nancy Y Ip
Journal:  Nat Commun       Date:  2019-07-25       Impact factor: 14.919

Review 8.  Role of apolipoprotein E in neurodegenerative diseases.

Authors:  Vo Van Giau; Eva Bagyinszky; Seong Soo A An; Sang Yun Kim
Journal:  Neuropsychiatr Dis Treat       Date:  2015-07-16       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.